8-K: Pulse Biosciences Announces Rights Offering Details, Aims to Raise Up to $60 Million

Pulse Biosciences has set the record date for its rights offering, aiming to raise up to $60 million through the sale of units consisting of common stock and warrants.

Summary

• Pulse Biosciences is conducting a rights offering to raise up to $60 million.
• The record date for the rights offering is May 16, 2024.
• Stockholders as of the record date will receive non-transferable subscription rights to purchase units.
• Each unit consists of one share of common stock and two warrants.
• The price per unit will be the lesser of $10 or the volume-weighted average price of the stock over the ten trading days leading up to the expiration date, currently contemplated to be June 13, 2024.
• The warrants are exercisable immediately upon completion of the rights offering and expire five years later.
• The company may redeem the warrants for $0.01 per share if the stock price reaches 150% or 200% of the exercise price for 20 consecutive trading days, but not before three months after issuance.
• The company expects to receive gross proceeds of up to $60 million, less expenses related to the offering, if fully subscribed.
• The rights offering includes an over-subscription right to purchase additional units that remain unsubscribed.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The rights offering is a necessary step for the company to raise capital, but it also introduces dilution risk for existing shareholders. The potential for future growth is present, but the success of the offering and the company's technology is not guaranteed.

Positives

• The rights offering provides an opportunity for existing shareholders to participate in the company's growth.
• The potential to raise up to $60 million could provide significant capital for the company's operations and development.
• The inclusion of warrants in the units could provide additional upside potential for investors.
• The over-subscription right allows existing shareholders to purchase additional units if available.

Negatives

• The rights offering will dilute existing shareholders' ownership if they do not participate.
• The company may not receive the full $60 million if the offering is not fully subscribed.
• The warrants are subject to redemption by the company under certain conditions, which could limit their potential value.
• The offering is subject to the registration statement becoming effective, which is not yet the case.

Risks

• The rights offering may not be fully subscribed, resulting in less capital raised than anticipated.
• The stock price could decline, potentially reducing the value of the units and warrants.
• The company's ability to redeem the warrants could limit their potential upside for investors.
• The registration statement for the offering has not yet become effective, which could delay or prevent the offering from proceeding.

Future Outlook

The company intends to use the proceeds from the rights offering to fund its operations and development of its CellFX nsPFA technology. The company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets.

Management Comments

• Pulse Biosciences is committed to health innovation that has the potential to improve the quality of life for patients.

Industry Context

The rights offering is a common method for companies to raise capital, particularly in the biotechnology sector where research and development require significant funding. Pulse Biosciences is focused on bioelectric medicine, a growing area of interest in the medical device industry.

Comparison to Industry Standards

• Rights offerings are a common method for biotech companies to raise capital, especially those in the development stage like Pulse Biosciences.
• The structure of the offering, including units with common stock and warrants, is typical for this type of financing.
• The warrant redemption terms are relatively standard, designed to protect the company from excessive dilution while providing potential upside for investors.
• Comparable companies in the medical device space, such as those developing novel ablation technologies, often utilize similar financing strategies to fund their research and development.

Stakeholder Impact

• Shareholders will have the opportunity to participate in the rights offering, potentially increasing their ownership stake.
• Employees may benefit from the company's increased financial stability and growth potential.
• Customers may benefit from the continued development of the company's technology.
• Creditors may view the capital raise positively, potentially improving the company's creditworthiness.

Next Steps

• The company will file a final prospectus before commencing the rights offering.
• Stockholders will need to decide whether to participate in the rights offering by the expiration date.
• The company will proceed with the rights offering once the registration statement becomes effective.

Key Dates

Keywords

rights offering, capital raise, stockholders, warrants, subscription rights, common stock, CellFX, nanosecond pulsed field ablation, nsPFA